In his new position, Dr Fuller will work closely with Oriel co-founder, president and COO Paul Atkins. Prior to joining Oriel, Dr Fuller has served in a number of senior positions at Aerovance, most recently as executive vice president of R&D, where he led the development of a novel protein for the treatment of asthma and eczema.
Dr Fuller has received his MD degree from St George’s Hospital Medical School. Dr Fuller is a fellow of the Royal College of Physicians and is clinically accredited in internal medicine and clinical pharmacology.
James Niedel, executive chairman of Oriel, said: “We are fortunate to attract someone of Rick’s background and stature to Oriel. His extensive knowledge of respiratory markets and product development will be critical as we prepare to begin clinical trials next year.”